BIOMAT Database Logo BIOMAT Database Logo

Clinical significance of e-antigen/anti-e, with special reference to HBc-antigen in the liver. 1977

S Furuta, and K Kiyosawa, and A Nagata, and Y Koike, and T Sahara, and K Furukawa, and Y Iijima, and S Yamamura, and H Komatsu, and K Kawahara, and M Miura, and Y Gibo, and K Sodeyama, and M Oda, and F Tsuda, and Y Akahane, and M Mayumi

e-antigen and anti-e were assayed in sera of asymptomatic HBs-Ag carriers and of patients with liver diseases. Thirteen out of 34 (38.2%) asymptomatic carriers were positive for e-antigen, which was in sharp contrast to the reports from USA and Europe. e-antigen was detected to a greater extent in patients with chronic active hepatitis, reversely anti-e in patients with chronic persistent hepatitis. However, e-antigen was found rarely in patients with cirrhosis and never in 23 cases with hepatoma positive for HBs-Ag. HBc-Ag in the liver was detected in 4 out of 8 e-antigen positive asymptomatic carriers and in 4 out of 5 patients with chronic liver diseases with e-antigen respectively, and moreover in 3 out of 14 anti-e positive cases, so that the presence of anti-e did not necessarily mean the negativity of HBc-Ag in the liver. Anti-HBc titer, however, was lower in anti-e positive sera than in e-antigen positive ones. This may implicate the decreased replication of HBV in cases with anti-e. These results emphasize that the investigation of e-antigen/anti-e is mandatory for the evaluation of the prognosis of asymptomatic carriers and of patients with chronic hepatitis.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008107 Liver Diseases Pathological processes of the LIVER. Liver Dysfunction,Disease, Liver,Diseases, Liver,Dysfunction, Liver,Dysfunctions, Liver,Liver Disease,Liver Dysfunctions
D002353 Carrier State The condition of harboring an infective organism without manifesting symptoms of infection. The organism must be readily transmissible to another susceptible host. Asymptomatic Carrier State,Asymptomatic Infection Carrier,Inapparent Infection Carrier,Presymptomatic Carrier State,Presymptomatic Infection Carrier,Super-spreader Carrier,Superspreader Carrier,Asymptomatic Carrier States,Asymptomatic Infection Carriers,Carrier State, Asymptomatic,Carrier State, Presymptomatic,Carrier States,Carrier, Super-spreader,Carrier, Superspreader,Carriers, Super-spreader,Carriers, Superspreader,Inapparent Infection Carriers,Infection Carrier, Asymptomatic,Infection Carrier, Inapparent,Infection Carrier, Presymptomatic,Presymptomatic Carrier States,Presymptomatic Infection Carriers,Super spreader Carrier,Super-spreader Carriers,Superspreader Carriers
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006510 Hepatitis B Antibodies Antibodies to the HEPATITIS B ANTIGENS, including antibodies to the surface (Australia) and core of the Dane particle and those to the "e" antigens. Anti-Australia Antigens,Anti-HBAg,Anti-Hepatitis B Antigens,Anti HBAg,Hepatitis B Virus Antibodies,Anti Australia Antigens,Anti Hepatitis B Antigens,Antibodies, Hepatitis B,Antigens, Anti-Australia,Antigens, Anti-Hepatitis B,B Antibodies, Hepatitis,B Antigens, Anti-Hepatitis,HBAg, Anti
D006511 Hepatitis B Antigens Antigens of the virion of the HEPATITIS B VIRUS or the Dane particle, its surface (HEPATITIS B SURFACE ANTIGENS), core (HEPATITIS B CORE ANTIGENS), and other associated antigens, including the HEPATITIS B E ANTIGENS. HBAg,Hepatitis B Antigen,Antigen, Hepatitis B,Antigens, Hepatitis B,B Antigen, Hepatitis,B Antigens, Hepatitis
D006512 Hepatitis B Core Antigens The hepatitis B antigen within the core of the Dane particle, the infectious hepatitis virion. HBcAg,Hepatitis B Core Antigen
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies

Related Publications

S Furuta, and K Kiyosawa, and A Nagata, and Y Koike, and T Sahara, and K Furukawa, and Y Iijima, and S Yamamura, and H Komatsu, and K Kawahara, and M Miura, and Y Gibo, and K Sodeyama, and M Oda, and F Tsuda, and Y Akahane, and M Mayumi
[Clinical significance of anti-HBc and IgM.anti-HBc].
April 1988, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae,
S Furuta, and K Kiyosawa, and A Nagata, and Y Koike, and T Sahara, and K Furukawa, and Y Iijima, and S Yamamura, and H Komatsu, and K Kawahara, and M Miura, and Y Gibo, and K Sodeyama, and M Oda, and F Tsuda, and Y Akahane, and M Mayumi
[Clinical significance of the Australia antigen with special reference to various antisera for detection of the antigen].
June 1972, Wiener medizinische Wochenschrift (1946),
S Furuta, and K Kiyosawa, and A Nagata, and Y Koike, and T Sahara, and K Furukawa, and Y Iijima, and S Yamamura, and H Komatsu, and K Kawahara, and M Miura, and Y Gibo, and K Sodeyama, and M Oda, and F Tsuda, and Y Akahane, and M Mayumi
[The significance of demonstration of anti-leukocyte antibodies with special reference to clinical requirements].
July 1958, Casopis lekaru ceskych,
S Furuta, and K Kiyosawa, and A Nagata, and Y Koike, and T Sahara, and K Furukawa, and Y Iijima, and S Yamamura, and H Komatsu, and K Kawahara, and M Miura, and Y Gibo, and K Sodeyama, and M Oda, and F Tsuda, and Y Akahane, and M Mayumi
Clinical Significance and Remaining Issues of Anti-HBc Antibody and HBV Core-Related Antigen.
March 2024, Diagnostics (Basel, Switzerland),
S Furuta, and K Kiyosawa, and A Nagata, and Y Koike, and T Sahara, and K Furukawa, and Y Iijima, and S Yamamura, and H Komatsu, and K Kawahara, and M Miura, and Y Gibo, and K Sodeyama, and M Oda, and F Tsuda, and Y Akahane, and M Mayumi
[Anti-HBc titer in HBeAg(e-antigen) and anti-HBe(anti-e) positive asymptomatic hepatitis B surface antigen (HBsAG) carriers].
January 1978, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
S Furuta, and K Kiyosawa, and A Nagata, and Y Koike, and T Sahara, and K Furukawa, and Y Iijima, and S Yamamura, and H Komatsu, and K Kawahara, and M Miura, and Y Gibo, and K Sodeyama, and M Oda, and F Tsuda, and Y Akahane, and M Mayumi
The significance of 'anti-HBc only' in the clinical virology laboratory.
July 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
S Furuta, and K Kiyosawa, and A Nagata, and Y Koike, and T Sahara, and K Furukawa, and Y Iijima, and S Yamamura, and H Komatsu, and K Kawahara, and M Miura, and Y Gibo, and K Sodeyama, and M Oda, and F Tsuda, and Y Akahane, and M Mayumi
Significance of anti-HBc alone serological status in clinical practice.
February 2017, The lancet. Gastroenterology & hepatology,
S Furuta, and K Kiyosawa, and A Nagata, and Y Koike, and T Sahara, and K Furukawa, and Y Iijima, and S Yamamura, and H Komatsu, and K Kawahara, and M Miura, and Y Gibo, and K Sodeyama, and M Oda, and F Tsuda, and Y Akahane, and M Mayumi
Diagnostic significance and clinical application of tumour-associated antigens in man with special reference to the carcinoembryonic antigen.
October 1977, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie,
S Furuta, and K Kiyosawa, and A Nagata, and Y Koike, and T Sahara, and K Furukawa, and Y Iijima, and S Yamamura, and H Komatsu, and K Kawahara, and M Miura, and Y Gibo, and K Sodeyama, and M Oda, and F Tsuda, and Y Akahane, and M Mayumi
The Sensation of Vibration, with Special Reference to its Clinical Significance.
October 1936, The Journal of neurology and psychopathology,
S Furuta, and K Kiyosawa, and A Nagata, and Y Koike, and T Sahara, and K Furukawa, and Y Iijima, and S Yamamura, and H Komatsu, and K Kawahara, and M Miura, and Y Gibo, and K Sodeyama, and M Oda, and F Tsuda, and Y Akahane, and M Mayumi
[Clinical significance of alpha 1-fetoglobulin, with special reference to diagnosis of primary liver cancer].
July 1969, Naika. Internal medicine,
Copied contents to your clipboard!